| | Business Summary | | Sheffield
Pharmaceuticals,
Inc.
is
a
specialty
pharmaceutical
company
focused
on
the
development
and
commercialization
of
later
stage
pharmaceutical
opportunities
utilizing
proprietary
pulmonary
delivery
technologies
over
a
range
of
therapeutic
areas.
Through
its
alliances
with
Elan
Corporation
plc,
Zambon
Group
SpA
and
Siemens
AG,
Sheffield
is
currently
developing
nine
respiratory
and
systemic
(non-respiratory)
therapies
to
be
delivered
through
the
Company's
Metered
Solution
Inhaler
and
Aerosol
Drug
Delivery
System. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | SHM
is
a
development
stage
company
engaged
in
the
development
of
drug
delivery
systems.
The
Company's
lead
products
are
respiratory
drugs
for
the
treatment
of
asthma
and
chronic
obstructive
pulmonary
disease.
For
the
six
months
ended
6/30/01,
revenues
totalled
$874
thousand,
up
from
$246
thousand.
Net
loss
rose
36%
to
$3.9
million.
Revenues
reflect
additional
respiratory
programs
in
development.
Higher
loss
suffered
from
increased
research
and
development
costs. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Thomas Fitzgerald, 50
Chairman | $214K | Loren Peterson, 44
Pres,
CEO | 214K | David Byron, 52
Exec.
VP of Scientific Affairs | 187K | Carl Siekmann, 57
Exec.
VP of Corp. Devel. | 186K | Scott Hoffman, 36
VP
of Fin. and Admin., Treasurer, Sec., CFO | 144K | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/shm.gif)